{"id":36301,"date":"2025-06-26T18:48:41","date_gmt":"2025-06-26T16:48:41","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/06\/26\/sf3b1k700e-neoantigen-is-a-cd8-t-cell-target-shared-across-human-myeloid-neoplasms\/"},"modified":"2025-06-26T18:48:41","modified_gmt":"2025-06-26T16:48:41","slug":"sf3b1k700e-neoantigen-is-a-cd8-t-cell-target-shared-across-human-myeloid-neoplasms","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/06\/26\/sf3b1k700e-neoantigen-is-a-cd8-t-cell-target-shared-across-human-myeloid-neoplasms\/","title":{"rendered":"SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Jun 26. doi: 10.1158\/2326-6066.CIR-24-0091. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Acquired mutations in spliceosome genes in early hematopoietic stem\/progenitor cells are common events in myelodysplastic neoplasms (MDS) and related myeloid malignancies. Mutations in the spliceosome factor subunit B1 (SF3B1) gene occur in \u226520% of MDS cases at conserved hotspots and in early neoplastic clones as driver events. Neoantigens from aberrant SF3B1 proteins could serve as shared T-cell therapy targets for SF3B1-mutated myeloid neoplasms. We identified a candidate neoantigen from the prevalent SF3B1K700E variant using in silico predictions of epitope processing and presentation, then validated presentation and immunogenicity in vitro. CD8+ T cells recognizing SF3B1K700E demonstrated high functional avidity and killed neoplastic myeloid cell lines and primary cells in an antigen-specific manner. We then sequenced, cloned, and transduced a SF3B1K700E-specific T-cell receptor (TCR) into 3rd-party T cells and confirmed that TCR transfer conferred antigen specificity and killing of neoplastic myeloid cells in vitro and in vivo. The data indicate that the SF3B1K700E neoantigen represents a promising T-cell target for patients with SF3B1-mutated MDS and acute myeloid leukemia.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40569290\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20250626124839&amp;v=2.18.0.post9+e462414\">40569290<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0091\">10.1158\/2326-6066.CIR-24-0091<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Jun 26. doi: 10.1158\/2326-6066.CIR-24-0091. Online ahead of print. ABSTRACT Acquired mutations in spliceosome genes in early hematopoietic stem\/progenitor cells are common events in myelodysplastic neoplasms (MDS) and related myeloid malignancies. Mutations in the spliceosome factor subunit B1 (SF3B1) gene occur in \u226520% of MDS cases at conserved hotspots and in early &#8230; <a title=\"SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/06\/26\/sf3b1k700e-neoantigen-is-a-cd8-t-cell-target-shared-across-human-myeloid-neoplasms\/\" aria-label=\"Read more about SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-36301","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/36301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=36301"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/36301\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=36301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=36301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=36301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}